Ibrilatazar is under clinical development by Ability Pharmaceuticals and currently in Phase III for Metastatic Pancreatic Cancer.

In 2023, 10.8 million people fell ill with tuberculosis (TB) with an estimated 1.25 million deaths globally. While 400,000 people were diagnosed with multi-drug resistant (MDR) and/or ...

Department of Molecular, Cell and Systems Biology, University of California Riverside, Riverside, USA Stowers Institute for Medical Research, Kansas City, USA ...